Abstract Details

Title Clinical and Disability Characteristics of Patients with Multiple Sclerosis Over Age 60 in a Large Multi-Center Database.

Topic Multiple Sclerosis

Presentation(s) S40 - Multiple Sclerosis: Clinical Trials (1:00 PM-1:12 PM)

Poster/Presentation
Number 001

Background As the peak prevalence of MS shifts as patients with the disease age, understanding the characteristics that define this older patient population to improve management strategies in this age group is critical.

Objective To determine the clinical and disability characteristics of patients with multiple sclerosis (MS) over age 60.

Design/Methods Demographics, MS disease history, iPad® based patient reported outcomes and neuroperformance tests were collected from 10 academic MS centers in the US and Europe utilizing the MSPATHS database (2016-2019).

Results We identified 2755 patients over age 60 from the MSPATHS database. Our cohort is characterized by: median age 66 years (IQR 63-70y), 67.2% female, 67.4% white, median disease duration of 25.0 years (IQR 15-34y). Disease course was relapsing-remitting (RR) (44.5%), with 19.9% secondary-progressive (SP), 11.7% primary-progressive (PP), and 10.1% progressive-relapsing (PR). Current disease modifying therapies were: glatiramer acetate (13.0%), interferons (8.1%), dimethyl fumarate (7.8%), teriflunomide (5.3%), fingolimod (4.3%) and none (30.1%). 37.4% of patients had a self-reported relapse in the prior 12 months, only 1.2% had a new gadolinium enhancing lesion, and 3.2% had a new T2 lesion in the prior 12 months. More RR patients lived at home without assistance (84.0%) and work full time (23.6%), compared to PP (61.2% and 15.2%) and SP (68.3% and 14.2%), respectively. The median Patient-Determined Disease Steps (PDDS) of: RR patients was 1 (IQR 0-3), PP was 5 (IQR 3-6), and SP 4 (IQR 3-6). Only 23.8% of RR required a walking aide, compared to 67.7% of PP and 65.2% of SP patients. Co-morbidities of hypertension, diabetes, and obesity appear similar among RR, PP and SP patients.

Conclusions Most patients over age 60 live at home without assistance, but a majority reports some difficulties with walking. Planned longitudinal analyses in this cohort will be helpful for management of this older population.

Authors/Disclosures
Le Hua, MD, FAAN (Cleveland Clinic) PRESENTER	Dr. Hua has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genentech. Dr. Hua has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for EMD Serono. Dr. Hua has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Horizon. Dr. Hua has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Hua has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genzyme. Dr. Hua has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. Dr. Hua has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Hua has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Dr. Hua has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for TG Therapuetics. The institution of Dr. Hua has received research support from Genentech.
	No disclosure on file
Carrie M. Hersh, DO, MSc, FAAN (Cleveland Clinic Lou Ruvo Center for Brain Health)	Dr. Hersh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Hersh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Hersh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech_GN41791. Dr. Hersh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genzyme. Dr. Hersh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Hersh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol-Myers Squibb . Dr. Hersh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TG Therapeutics. Dr. Hersh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Hersh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Horizon Therapeutics. Dr. Hersh has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Dr. Hersh has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Genzyme. Dr. Hersh has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. The institution of Dr. Hersh has received research support from Biogen. The institution of Dr. Hersh has received research support from Novartis. The institution of Dr. Hersh has received research support from Genentech_GN41791. The institution of Dr. Hersh has received research support from PCORI. The institution of Dr. Hersh has received research support from Bristol Myers Squibb.
Ellen M. Mowry, MD, FAAN (Johns Hopkins University)	Dr. Mowry has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BeCareLink, LLC. The institution of Dr. Mowry has received research support from Biogen. The institution of Dr. Mowry has received research support from Genentech. Dr. Mowry has received publishing royalties from a publication relating to health care.
Kathryn Fitzgerald, PhD (Johns Hopkins University)	The institution of Dr. Fitzgerald has received research support from NIH. The institution of Dr. Fitzgerald has received research support from National MS Society.

��ɫ��

��ɫ��